Kornitzer Capital Management Inc. KS lessened its stake in shares of OptiNose Inc (NASDAQ:OPTN) by 90.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,000 shares of the company’s stock after selling 317,980 shares during the period. Kornitzer Capital Management Inc. KS owned 0.08% of OptiNose worth $435,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of OPTN. Massachusetts Financial Services Co. MA increased its stake in OptiNose by 1.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 703,962 shares of the company’s stock worth $19,697,000 after acquiring an additional 9,763 shares during the period. Wells Fargo & Company MN increased its stake in OptiNose by 60.0% during the 2nd quarter. Wells Fargo & Company MN now owns 454,160 shares of the company’s stock worth $12,708,000 after acquiring an additional 170,382 shares during the period. State of Wisconsin Investment Board bought a new position in OptiNose during the 2nd quarter worth $464,000. EAM Investors LLC bought a new position in OptiNose during the 2nd quarter worth $1,082,000. Finally, EAM Global Investors LLC bought a new position in OptiNose during the 2nd quarter worth $1,365,000. Hedge funds and other institutional investors own 50.30% of the company’s stock.
Shares of OPTN opened at $7.89 on Friday. OptiNose Inc has a 52-week low of $7.33 and a 52-week high of $30.00. The company has a current ratio of 10.44, a quick ratio of 10.13 and a debt-to-equity ratio of 0.51.
OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.11. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.57 million. As a group, equities research analysts predict that OptiNose Inc will post -2.93 earnings per share for the current year.
A number of equities analysts have commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of OptiNose in a research note on Wednesday, August 15th. Zacks Investment Research lowered OptiNose from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Piper Jaffray Companies set a $30.00 price target on OptiNose and gave the company a “buy” rating in a research note on Tuesday, August 14th. Finally, BMO Capital Markets decreased their price target on OptiNose from $30.00 to $28.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. OptiNose presently has an average rating of “Buy” and a consensus price target of $28.75.
ILLEGAL ACTIVITY NOTICE: “Kornitzer Capital Management Inc. KS Sells 317,980 Shares of OptiNose Inc (OPTN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/12/07/kornitzer-capital-management-inc-ks-sells-317980-shares-of-optinose-inc-optn.html.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.